We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
Read MoreHide Full Article
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) is scheduled to report second-quarter 2020 results on Jul 30, after the market closes.
The company’s surprise record is pretty impressive with earnings beat in each of the trailing four quarters, the average being 27.65%. In the last reported quarter, Vertex delivered an earnings surprise of 39.89%.
Shares of Vertex have rallied 29.9% in the year so far compared with the industry’s 9.8% increase.
Let’s see, how things are shaping up for the quarter to be reported.
Factors at Play
Sales growth in the last reported quarter was driven by a rapid uptake of the company’s newly-launched CF medicine Trikafta, a trend that most likely continued in the second quarter as well.
In fact, first-quarter sales of Trikafta benefited from a few early refills by patients and an advanced purchasing by some ex-U.S. governments due to Covid-19 disruptions. However, this benefit is likely to have reversed over the course of the year. Moreover, since a high percentage of currently eligible patients is already on Trikafta, the sales growth rate might have been slower for Trikafta in the second quarter. Further, this momentum is also expected to be carried in the remaining quarters of 2020.
In June, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending an approval for the company’s triple combination cystic fibrosis regimen, Kaftrio. On getting a nod in the EU, about 10,000 new patients with one minimal function mutation and one F508del mutation will be eligible to be treated with Kaftrio.
In the EU, a regulatory application for Trikafta (known as Kaftrio) is under review with an approval expected later in 2020.
The strong adoption of Trikafta resulted in the sales erosion of Vertex’s other CF drugs and its existing combinations, namely Kalydeco, Orkambi and Symdeko. In the last reported quarter, all the other three CF medicines saw a year-over-year decline in sales, a trend that most likely continued in the to-be-reported quarter as well.
Meanwhile, higher international revenues owing to a strong patient uptake of Orkambi and Symkevi following the completion of reimbursement arrangements in key ex-U.S. countries like England and France in 2019 might have boosted the company’s sales in the second quarter
Notably, in the last reported quarter, management stated that the COVID-19 pandemic prompted some CF centers to limit their non-emergency interactions with patients, which might impact the rate of future treatment initiations. As a result, this could limit the uptake of the company’s CF medicines in the near term. We expect an update on the same at upcoming earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Vertex this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as shown below.
Earnings ESP: Vertex has an Earnings ESP of +3.91%, representing the percentage difference between the Most Accurate Estimate of $2.21 and the Zacks Consensus Estimate of $2.13. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:Vertex has a Zacks Rank #4 (Sell), currently.
Vertex Pharmaceuticals Incorporated Price and EPS Surprise
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +8.12% and a Zacks Rank #3 at present. The company is scheduled to release earnings results on Aug 5.
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +6.69% and a Zacks Rank of 2, currently. The company is scheduled to release earnings results on Jul 30.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) is scheduled to report second-quarter 2020 results on Jul 30, after the market closes.
The company’s surprise record is pretty impressive with earnings beat in each of the trailing four quarters, the average being 27.65%. In the last reported quarter, Vertex delivered an earnings surprise of 39.89%.
Shares of Vertex have rallied 29.9% in the year so far compared with the industry’s 9.8% increase.
Let’s see, how things are shaping up for the quarter to be reported.
Factors at Play
Sales growth in the last reported quarter was driven by a rapid uptake of the company’s newly-launched CF medicine Trikafta, a trend that most likely continued in the second quarter as well.
In fact, first-quarter sales of Trikafta benefited from a few early refills by patients and an advanced purchasing by some ex-U.S. governments due to Covid-19 disruptions. However, this benefit is likely to have reversed over the course of the year. Moreover, since a high percentage of currently eligible patients is already on Trikafta, the sales growth rate might have been slower for Trikafta in the second quarter. Further, this momentum is also expected to be carried in the remaining quarters of 2020.
In June, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending an approval for the company’s triple combination cystic fibrosis regimen, Kaftrio. On getting a nod in the EU, about 10,000 new patients with one minimal function mutation and one F508del mutation will be eligible to be treated with Kaftrio.
In the EU, a regulatory application for Trikafta (known as Kaftrio) is under review with an approval expected later in 2020.
The strong adoption of Trikafta resulted in the sales erosion of Vertex’s other CF drugs and its existing combinations, namely Kalydeco, Orkambi and Symdeko. In the last reported quarter, all the other three CF medicines saw a year-over-year decline in sales, a trend that most likely continued in the to-be-reported quarter as well.
Meanwhile, higher international revenues owing to a strong patient uptake of Orkambi and Symkevi following the completion of reimbursement arrangements in key ex-U.S. countries like England and France in 2019 might have boosted the company’s sales in the second quarter
Notably, in the last reported quarter, management stated that the COVID-19 pandemic prompted some CF centers to limit their non-emergency interactions with patients, which might impact the rate of future treatment initiations. As a result, this could limit the uptake of the company’s CF medicines in the near term. We expect an update on the same at upcoming earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Vertex this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as shown below.
Earnings ESP: Vertex has an Earnings ESP of +3.91%, representing the percentage difference between the Most Accurate Estimate of $2.21 and the Zacks Consensus Estimate of $2.13. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:Vertex has a Zacks Rank #4 (Sell), currently.
Vertex Pharmaceuticals Incorporated Price and EPS Surprise
Vertex Pharmaceuticals Incorporated price-eps-surprise | Vertex Pharmaceuticals Incorporated Quote
Stocks to Consider
Here are some biotech stocks with the right mix of elements to beat on earnings this season:
Agenus Inc. (AGEN - Free Report) has an Earnings ESP of +15.85% and a Zacks Rank #2, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +8.12% and a Zacks Rank #3 at present. The company is scheduled to release earnings results on Aug 5.
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +6.69% and a Zacks Rank of 2, currently. The company is scheduled to release earnings results on Jul 30.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>